Cell viability was assessed by MTT assay. TCL cells were cultured in 96-well plates at a density of 0.1 × 106 cells per ml with 200 µL of media per well and were treated with the indicated concentrations of drugs for 72 h. After drug treatment, MTT was added, and viability was quantified using a microplate reader. The pro-apoptotic effects of ruxolitinib and Reolysin were quantified by propidium iodide staining and fluorescence activated cell sorting (PI-FACS) analysis of sub-G0/G1 DNA and quantification of active caspase-3 positive cells by flow cytometry using a commercial kit (BD Biosciences, San Jose, CA, USA).
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.